meta-analysis of cholinesterase inhibitors in Alzheimer's disease (JAMA 2003)
Jump to navigation
Jump to search
Introduction
Study characteristics:
- 29 trials, since 1989
- 9 different cholinesterase inhibitors
- 9000 patients with mild to moderate Alzheimer's disease
- trials 2-12 months, most 4-6 months
Results:
- modest improvement in both neuropsychiatric & functional outcomes
- effect size = 0.1 SD; the lower limit of clinically detectable change
More general terms
References
- ↑ Journal Watch 23(4):36, 2003 Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 289:210, 2003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12517232